Flipkart FY22 Losses Widen To Over Rs 7,800 Crore
E-commerce major Flipkart's losses widened to over Rs 7,800 crore in the financial year 2021-22 based on performance of its business-to-business unit Flipkart India and B2C e-commerce unit Flipkart Internet, according to regulatory filings.
According to filings, the combined loss of both entities stood at Rs 5,352 crore in the financial year 2020-21.
Flipkart Internet, comprising online business-to-consumer platforms, has reported widening of loss to Rs 4,399 crore in FY22 from Rs 2,907 crore in FY21.
This includes the performance of Flipkart Group firms like Myntra, Instakart etc. The B2BÂ unit, Flipkart India -- earlier called Walmart India -- reported widening of loss to Rs 3,413 crore in FY22 from Rs 2,445.6 crore in FY21.
The net income of Flipkart, however, increased by close to 20 per cent to about Rs 61,836 crore in 2021-22 with Flipkart India contributing Rs 51,176 core and Flipkart Internet registering a revenue of Rs 10,660 crore.
Combined revenue of the e-commerce major in 2020-21 was Rs 51,465 crore with Flipkart India and Flipkart Internet contributing Rs 43,349 crore and Rs 8,116 crore respectively.
Queries sent to Flipkart in this regard did not elicit any reply.
According to market research firm Redseer, it has been leading total sales in India during festive season.
According to the consulting firm report, Flipkart is estimated to have led the first week of festive season sale that was held in the last week of September with the company cornering 62 per cent or Rs 24,800 crore worth of gross merchandise value from total sales of Rs 40,000 crore.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.